Compare ConocoPhillips (COP) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Novavax Inc — how do they compare? ConocoPhillips trades at $111.54 (market cap $136.29B), while Novavax Inc trades at $8.5 (market cap $1.38B). The key difference: ConocoPhillips is far larger — about 98.8× Novavax Inc's market cap, and ConocoPhillips pays a 3% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| COP | NVAX | |
|---|---|---|
Market Cap | $136.29B | $1.38B |
Sector | Energy | Health |
52-Week High | $133.80 | $11.19 |
52-Week Low | $85.66 | $6.22 |
Enterprise Value | $153.25B | $889.29M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
